科研动态期刊摘要

[论著] Trevogrumab(抗GDF8抗体)联合或不联合garetosmab(抗激活素A抗体)用于预防肥胖人群在接受司美格鲁肽诱导减重期间的肌肉流失(COURAGE):一项分为两部分、2期、双盲、安慰剂对照、随机试验

The Lancet Online First · 2026-11-12

完整摘要 · 中文译文

背景:由GLP-1受体激动剂诱导的快速减重伴随着显著的肌肉流失。GDF8(肌肉生长抑制素)和激活素A(ActA)通过ActRIIA/B受体发挥作用,是肌肉量的负性调节因子。本研究旨在评估阻断GDF8的抗体(trevogrumab)和阻断ActA的抗体(garetosmab)对司美格鲁肽诱导的体重和肌肉流失的影响。 方法:COURAGE是一项分为两部分的2期、双盲、安慰剂对照、随机试验。这项多中心(60个研究中心)、基于美国的试验纳入了年龄18-80岁、患有肥胖(BMI ≥30 kg/m2)的参与者。在A部分中,参与者接受semaglutide(滴定至每周皮下注射2·4 mg)治疗26周,并随机分配(1:1:1:1)接受以下伴随治疗之一:安慰剂、trevogrumab 200 mg、trevogrumab 400 mg,或trevogrumab 400 mg联合garetosmab 10 mg/kg。Trevogrumab每周皮下给药,garetosmab每4周静脉给药。A部分还包括随后的semaglutide撤药期,此时参与者(在基线时每组内按1:1随机分配)接受trevogrumab 400 mg或安慰剂治疗额外26周。在B部分中,参与者接受semaglutide治疗52周,并随机分配(1:2:2)接受安慰剂、trevogrumab 25 mg或trevogrumab 75 mg的伴随治疗。各组按性别、BMI(<35 kg/m2 vs ≥35 kg/m2)以及参与评估大腿肌肉体积的探索性MRI子研究进行分层。研究参与者、主要研究者和研究中心人员在研究全程对所有随机化分配设盲。主要终点是瘦体重、脂肪量和体重从基线至第26周(A部分)或第52周(B部分)的百分比变化。疗效和安全性分析在所有接受至少一剂研究药物的随机分配参与者中进行(疗效按随机分配分析;安全性按实际治疗分析)。COURAGE i 已在ClinicalTrials.gov注册,注册号为NCT06299098,目前状态为进行中、尚未招募。 研究结果:2024年6月21日至2025年4月14日期间共纳入975名参与者。平均年龄为49.0岁(标准差13.2),平均BMI为36.7 kg/m²(标准差5.0);975名参与者中627名(64%)为女性,348名(36%)为男性。在A部分(n=605,其中n=599至少接受了一剂研究药物),第26周时司美格鲁肽联合安慰剂组观察到瘦体重显著下降(-6.6%[95%CI -7.4至-5.7]);与司美格鲁肽联合安慰剂相比,估计治疗差异(ETD)在司美格鲁肽联合trevogrumab 200 mg组为+3.1%(95%CI 1.9至4.3),在司美格鲁肽联合trevogrumab 400 mg组为+2.7%(1.5至4.0),在司美格鲁肽联合trevogrumab 400 mg联合garetosmab 10 mg/kg组为+4.5%(3.1至5.9)。在B部分(n=376),司美格鲁肽联合安慰剂组从基线至第52周瘦体重百分比变化为-7.3%(-8.8至-5.8);与司美格鲁肽联合安慰剂相比,ETD在司美格鲁肽联合trevogrumab 25 mg组为+1.5%(-0.3至3.3),在司美格鲁肽联合trevogrumab 75 mg组为+3.1%(1.3至4.9)。A部分中司美格鲁肽联合安慰剂组脂肪量相对基线的变化为-15.6%(-17.4至-13.9);A部分中司美格鲁肽联合trevogrumab 400 mg组(-3.4%[-5.9至-0.9])和司美格鲁肽联合trevogrumab 400 mg联合garetosmab 10 mg/kg组(-11.7%[-14.4至-9.0])的ETD具有显著性。A部分其他组及B部分任何组与司美格鲁肽联合安慰剂相比,脂肪量变化均无显著差异。A部分中司美格鲁肽联合安慰剂组体重百分比变化为-10.6(-11.6至-9.7);ETD在s 司美格鲁肽联合trevogrumab 400 mg联合garetosmab 10 mg/kg组(-2.7 [-4.1至-1.2])。A部分其他各组及B部分任何组与司美格鲁肽联合安慰剂相比,体重变化均无显著差异。司美格鲁肽联合trevogrumab(25 mg、75 mg、200 mg或400 mg)总体耐受性良好,安全性特征与司美格鲁肽联合安慰剂相似;然而,司美格鲁肽联合trevogrumab 400 mg联合garetosmab 10 mg/kg组的严重不良事件发生率较高(149例中14例[9%])和治疗中止率较高(149例中48例[32%])。胃肠道不良事件为最常报告的不良事件,各治疗组发生率相似。肌肉痉挛在司美格鲁肽联合trevogrumab 400 mg联合garetosmab 10 mg/kg组的发生率(149例中61例[41%])高于司美格鲁肽联合trevogrumab 200 mg或400 mg组(299例中23例[8%])及司美格鲁肽联合安慰剂组(151例中7例[5%])。大多数不良事件严重程度为轻至中度。研究期间发生2例死亡,均发生于司美格鲁肽联合trevogrumab 400 mg联合garetosmab 10 mg/kg组;未发现治疗与这些事件之间的因果关系。 解读:本研究证实了单用trevogrumab抑制GDF8作为一种总体耐受良好的策略,可在GLP-1受体激动剂诱导的体重减轻期间保留瘦体重的概念验证。尽管加用garetosmab抑制ActA进一步改善了体成分和体重减轻,但联合用药并未显示出良好的安全性和耐受性。需要进一步研究以了解体重减轻期间体成分的改善是否可能保护身体功能和整体代谢健康。 资助:Regeneron Pharmaceuticals, Inc.

完整摘要 · 英文原文

BACKGROUND: Rapid weight loss, as induced by GLP-1 receptor agonists, is accompanied by pronounced muscle loss. GDF8 (myostatin) and activin A (ActA), acting via ActRIIA/B receptors, are negative regulators of muscle mass. The aim of this study was to evaluate the effect of antibodies blocking GDF8 (trevogrumab) and ActA (garetosmab) on semaglutide-induced weight and muscle loss. METHODS: COURAGE is a two-part, phase 2, double-blind, placebo-controlled, randomised trial. This multicentre (60 sites), US-based trial enrolled participants aged 18-80 years with obesity (BMI ≥30 kg/m2). In part A, participants were treated for 26 weeks with semaglutide (titrated to 2·4 mg subcutaneously weekly) in addition to a randomly assigned (1:1:1:1) concomitant treatment: placebo, trevogrumab 200 mg, trevogrumab 400 mg, or trevogrumab 400 mg and garetosmab 10 mg/kg. Trevogrumab was administered subcutaneously weekly and garetosmab was administered intravenously every 4 weeks. Part A also included a subsequent semaglutide withdrawal period, at which point participants (randomly assigned at baseline 1:1 within each group) received either trevogrumab 400 mg or placebo for an additional 26 weeks. In part B, participants were treated with semaglutide for 52 weeks and randomly assigned (1:2:2) to concomitant treatment with placebo, trevogrumab 25 mg, or trevogrumab 75 mg. Groups were stratified according to sex, BMI (<35 kg/m2vs ≥35 kg/m2), and participation in an exploratory MRI substudy assessing thigh muscle volume. Study participants, the principal investigators, and study site personnel were masked to all randomisation assignments throughout the study. Primary endpoints were percent change in lean mass, fat mass, and bodyweight from baseline to week 26 (part A) or week 52 (part B). Efficacy and safety analyses were done in all randomly assigned participants who received at least one dose of a study drug (efficacy, as randomly assigned; safety, as treated). COURAGE is registered with ClinicalTrials.gov, NCT06299098, and is currently active, not recruiting. FINDINGS: 975 participants were enrolled between June 21, 2024, and April 14, 2025. Mean age was 49·0 years (SD 13·2) and mean BMI was 36·7 kg/m2 (SD 5·0); 627 (64%) of 975 participants were female and 348 (36%) were male. In part A (n=605, of whom n=599 received at least one dose of study drug), a substantial decrease in lean mass was observed in the semaglutide plus placebo group at week 26 (-6·6% [95% CI -7·4 to -5·7]); the estimated treatment difference (ETD) versus semaglutide plus placebo was +3·1% (95% CI 1·9 to 4·3) with semaglutide plus trevogrumab 200 mg, +2·7% (1·5 to 4·0) with semaglutide plus trevogrumab 400 mg, and +4·5% (3·1 to 5·9) with semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg. In part B (n=376), lean mass percent change from baseline to week 52 for semaglutide plus placebo was -7·3% (-8·8 to -5·8); the ETD versus semaglutide plus placebo was +1·5% (-0·3 to 3·3) for semaglutide plus trevogrumab 25 mg, and +3·1% (1·3 to 4·9) for semaglutide plus trevogrumab 75 mg. Change from baseline in fat mass in part A was -15·6% (-17·4 to -13·9) in the semaglutide plus placebo group; the ETD was significant in the semaglutide plus trevogrumab 400 mg group (-3·4% [-5·9 to -0·9]) and the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group (-11·7% [-14·4 to -9·0]) in part A. No other groups in part A nor any in part B had significantly different changes in fat mass compared with semaglutide plus placebo. Percent change in bodyweight in part A was -10·6 (-11·6 to -9·7) in the semaglutide plus placebo group; the ETD was significant for the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group (-2·7 [-4·1 to -1·2]). No other groups in part A nor any in part B had significantly different changes in bodyweight compared with semaglutide plus placebo. Semaglutide plus trevogrumab (25 mg, 75 mg, 200 mg, or 400 mg) was generally well tolerated with a safety profile similar to semaglutide plus placebo; however, semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg had a high incidence of serious adverse events (14 [9%] of 149) and treatment discontinuations (48 [32%] of 149). Gastrointestinal adverse events were the most commonly reported, and they occurred with similar incidence across treatment groups. Muscle spasms occurred more frequently in the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group (61 [41%] of 149) compared with the semaglutide plus trevogrumab 200 mg or 400 mg groups (23 [8%] of 299) and semaglutide plus placebo groups (seven [5%] of 151). Most adverse events were mild to moderate in severity. Two deaths occurred during the study, both in the semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg group; a causal association between treatment and these events was not identified. INTERPRETATION: This study establishes proof of concept for GDF8 inhibition by trevogrumab alone as a generally well tolerated strategy to preserve lean mass during GLP-1 receptor agonist-induced weight loss. Although the addition of ActA inhibition by garetosmab further improved body composition and weight loss, the combination did not have favourable safety and tolerability. Further study is required to understand whether improved body composition during weight loss might preserve physical function and overall metabolic health. FUNDING: Regeneron Pharmaceuticals, Inc.

English
[Articles] Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界